Viskase Holdings, Inc. 8-K

What Happened

• Viskase Holdings, Inc. (formerly Enzon Pharmaceuticals, Inc.) filed an 8-K reporting that, after the March 26, 2026 merger with Viskase Companies, Inc., its Audit Committee on April 14, 2026 appointed Grant Thornton LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The Board unanimously ratified the appointment. Grant Thornton previously served as Viskase’s auditor prior to the merger. EisnerAmper LLP, Enzon’s pre-merger auditor, was informed on April 15, 2026 that it was dismissed.

Key Details

• Merger closing date: March 26, 2026; company filed a Certificate of Amendment to change its name to Viskase Holdings, Inc.
• Auditor appointment: Grant Thornton LLP appointed April 14, 2026; engagement subject to satisfactory client acceptance procedures.
• Prior auditor: EisnerAmper’s audit reports for fiscal years ended Dec 31, 2025 and Dec 31, 2024 were unqualified (no adverse or disclaimer opinions) and contained no qualifications for uncertainties, scope, or accounting principles.
• No disagreements or “reportable events” between the company and EisnerAmper for Jan 1–Dec 31, 2025 and through Apr 15, 2026; EisnerAmper’s concurrence letter dated April 16, 2026 is filed as Exhibit 16.1.

Why It Matters

• Auditor changes affect financial statement review and investor confidence. The appointment of Grant Thornton (Viskase’s prior auditor) follows the merger and may reflect continuity with Viskase accounting practices.
• The filing confirms that EisnerAmper’s past audits were clean and that there were no unresolved disagreements or reportable events, which reduces near-term audit-related risk for investors.
• The Grant Thornton engagement is still subject to client acceptance procedures, so investors should watch subsequent filings for final engagement confirmation and any related disclosures.